{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:27:46Z","timestamp":1783002466398,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s40265-014-0342-1","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T13:28:10Z","timestamp":1420464490000},"page":"197-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Droxidopa: A Review of Its Use in Symptomatic Neurogenic Orthostatic Hypotension"],"prefix":"10.1007","volume":"75","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"issue":"4","key":"342_CR1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00002826-199108000-00002","volume":"14","author":"R Freeman","year":"1991","unstructured":"Freeman R, Landsberg L. The treatment of orthostatic hypotension with dihydroxyphenylserine. Clin Neuropharmacol. 1991;14(4):296\u2013304.","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"342_CR2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1017\/S0317167100016528","volume":"41","author":"MJ Berger","year":"2014","unstructured":"Berger MJ, Kimpinski K. A practical guide to the treatment of neurogenic orthostatic hypotension. Can J Neurol Sci. 2014;41(2):156\u201363.","journal-title":"Can J Neurol Sci."},{"issue":"12","key":"342_CR3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40265-013-0097-0","volume":"73","author":"C Schroeder","year":"2013","unstructured":"Schroeder C, Jordan J, Kaufmann H. Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs. 2013;73(12):1267\u201379.","journal-title":"Drugs."},{"key":"342_CR4","unstructured":"Lundbeck NA Ltd. NORTHERA\u2122 (droxidopa) capsules, for oral use: US prescribing information. 2014. http:\/\/www.northera.com . Accessed 10 Dec 2014."},{"issue":"3\u20134","key":"342_CR5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1527-3466.2006.00189.x","volume":"24","author":"DS Goldstein","year":"2006","unstructured":"Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006;24(3\u20134):189\u2013203.","journal-title":"Cardiovasc Drug Rev."},{"issue":"Suppl","key":"342_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-3-211-45295-0_71","volume":"70","author":"H Kaufmann","year":"2006","unstructured":"Kaufmann H. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm. 2006;70(Suppl):477\u201384.","journal-title":"J Neural Transm."},{"issue":"1","key":"342_CR7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0091270010363476","volume":"51","author":"DS Goldstein","year":"2011","unstructured":"Goldstein DS, Holmes C, Sewell LT, et al. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. J Clin Pharmacol. 2011;51(1):66\u201374.","journal-title":"J Clin Pharmacol."},{"issue":"Suppl 1","key":"342_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10286-007-1002-2","volume":"18","author":"H Kaufmann","year":"2008","unstructured":"Kaufmann H. L-dihydroxyphenylserine (droxidopa): a new therapy for neurogenic orthostatic hypotension. The US experience. Clin Auton Res. 2008;18(Suppl 1):19\u201324.","journal-title":"The US experience. Clin Auton Res."},{"issue":"6","key":"342_CR9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000083721.49847.D7","volume":"108","author":"H Kaufmann","year":"2003","unstructured":"Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724\u20138.","journal-title":"Circulation."},{"issue":"6","key":"342_CR10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10286-004-0221-z","volume":"14","author":"DS Goldstein","year":"2004","unstructured":"Goldstein DS, Holmes C, Kaufmann H, et al. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004;14(6):363\u20138.","journal-title":"Clin Auton Res."},{"issue":"5","key":"342_CR11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00605999","volume":"23","author":"T Suzuki","year":"1982","unstructured":"Suzuki T, Higa S, Sakoda S, et al. Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy. Eur J Clin Pharmacol. 1982;23(5):463\u20138.","journal-title":"Eur J Clin Pharmacol."},{"issue":"11","key":"342_CR12","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1212\/WNL.34.11.1446","volume":"34","author":"T Suzuki","year":"1984","unstructured":"Suzuki T, Sakoda S, Ueji M, et al. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Neurology. 1984;34(11):1446\u201350.","journal-title":"Neurology."},{"issue":"18","key":"342_CR13","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/0006-2952(87)90223-1","volume":"36","author":"T Kato","year":"1987","unstructured":"Kato T, Karai N, Katsuyama M, et al. Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain: comparison with that of L-DOPA. Biochem Pharmacol. 1987;36(18):3051\u20137.","journal-title":"Biochem Pharmacol."},{"key":"342_CR14","unstructured":"US Food and Drug Administration. Droxidopa: medical review. Application number: 203202Orig1s000. 2014. http:\/\/www.fda.gov . Accessed 10 Dec 2014."},{"issue":"Suppl 1","key":"342_CR15","first-page":"S425","volume":"27","author":"P LeWitt","year":"2012","unstructured":"LeWitt P, Gorny S. Analysis of efficacy and safety outcomes in patients treated with droxidopa in combination with other drug classes [abstract no. 1294]. Mov Disord. 2012;27(Suppl 1):S425\u20136.","journal-title":"Mov Disord."},{"issue":"2","key":"342_CR16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02260889","volume":"3","author":"H Kaufmann","year":"1991","unstructured":"Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm. 1991;3(2):143\u20138.","journal-title":"J Neural Transm."},{"key":"342_CR17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02298955","volume":"11","author":"CJ Mathias","year":"2001","unstructured":"Mathias CJ, Senard J-M, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11:235\u201342.","journal-title":"Clin Auton Res."},{"key":"342_CR18","first-page":"272","volume":"17","author":"CJ Mathias","year":"2007","unstructured":"Mathias CJ, Senard JM, Cortelli P. A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy or Parkinson\u2019s disease [abstract]. Clin Auton Res. 2007;17:272.","journal-title":"Clin Auton Res."},{"key":"342_CR19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/13506129609045516","volume":"3","author":"L Wikstrom","year":"1996","unstructured":"Wikstrom L, Bjerle P, Boman K. L-threo-DOPS treatment of orthostatic hypotension in Swedish patients with familial amyloidotic polyneuropathy (TTR-met30). Amyloid J Protein Fold Disord. 1996;3:162\u20136.","journal-title":"Amyloid J Protein Fold Disord."},{"issue":"4","key":"342_CR20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1212\/WNL.0000000000000615","volume":"83","author":"H Kaufmann","year":"2014","unstructured":"Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328\u201335.","journal-title":"Neurology."},{"key":"342_CR21","doi-asserted-by":"crossref","unstructured":"Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2014. doi: 10.1161\/HYPERTENSIONAHA.114.04035 .","DOI":"10.1161\/HYPERTENSIONAHA.114.04035"},{"issue":"1","key":"342_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JPD-130259","volume":"4","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson\u2019s disease (NOH306A). J Parkinsons Dis. 2014;4(1):57\u201365.","journal-title":"J Parkinsons Dis."},{"key":"342_CR23","doi-asserted-by":"crossref","unstructured":"Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson\u2019s disease (nOH306B). Mov Disord. 2014. doi: 10.1002\/mds.26086 .","DOI":"10.1002\/mds.26086"},{"issue":"Suppl 1","key":"342_CR24","first-page":"S424","volume":"27","author":"S Isaacson","year":"2012","unstructured":"Isaacson S, Shill H, Vernino S, et al. Durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH 303) [abstract no. 1291]. Mov Disord. 2012;27(Suppl 1):S424\u20135.","journal-title":"Mov Disord."},{"issue":"Suppl 1","key":"342_CR25","first-page":"S426","volume":"27","author":"C Mathias","year":"2012","unstructured":"Mathias C, Low P, Freeman R, et al. Integrated efficacy analysis of droxidopa in 2 double-blind, placebo-controlled phase 3 studies in patients with neurogenic orthostatic hypotension [abstract no. 1296]. Mov Disord. 2012;27(Suppl 1):S426.","journal-title":"Mov Disord."},{"issue":"19","key":"342_CR26","first-page":"e203","volume":"80","author":"S Isaacson","year":"2013","unstructured":"Isaacson S, Hauser R, Szakacs C, et al. Droxidopa treatment impact on orthostatic symptoms and standing systolic blood pressure in patients with Parkinson\u2019s disease (PD) and symptomatic neurogenic orthostatic hypotension (NOH) [abstract]. Neurology. 2013;80(19):e203.","journal-title":"Neurology."},{"issue":"Suppl 1","key":"342_CR27","first-page":"S171","volume":"28","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Jerome LP, Schwieterman WD, et al. Impact of droxidopa treatment on falls and fall related injuries in patients with Parkinson\u2019s disease and symptomatic neurogenic orthostatic hypotension (study 306) [abstract no. 481]. Mov Disord. 2013;28(Suppl 1):S171.","journal-title":"Mov Disord."},{"issue":"Suppl 1","key":"342_CR28","first-page":"S428","volume":"27","author":"H Shill","year":"2012","unstructured":"Shill H, Vernino S, Hutchman R, et al. A multicenter, open-label study to assess the long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension (NOH 304) [abstract no. 1302]. Mov Disord. 2012;27(Suppl 1):S428.","journal-title":"Mov Disord."},{"issue":"1","key":"342_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00129784-200202010-00004","volume":"2","author":"M Lamarre-Cliche","year":"2002","unstructured":"Lamarre-Cliche M. Drug treatment of orthostatic hypotension because of autonomic failure or neurocardiogenic syncope. Am J Cardiovasc Drugs. 2002;2(1):23\u201335.","journal-title":"Am J Cardiovasc Drugs."},{"key":"342_CR30","unstructured":"Upsher-Smith Laboratories Inc. Midodrine HCl tablets: US prescribing information. 2012. http:\/\/www.upsher-smith.com\/ . Accessed 10 Dec 2014."},{"issue":"2","key":"342_CR31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10286-011-0146-2","volume":"22","author":"H Kaufmann","year":"2012","unstructured":"Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79\u201390.","journal-title":"Clin Auton Res."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0342-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0342-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0342-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T16:36:18Z","timestamp":1598632578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0342-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0342-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,6]]}}}